lopinavir/ritonavir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death or transfer to ICUdetailed results RECOVERY, 2020 1.09 [0.99; 1.20]
1.09 [0.99 ; 1.20 ] RECOVERY, 2020 1 0% 4,836 NA not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
Hung et al., 2020 (REV) 2.11 [0.04; 108.31]
Nojomi, 2020 (REV) 2.04 [0.18; 23.27]
Nojomi, 2020 2.04 [0.18; 23.27]
RECOVERY, 2020 1.03 [0.91; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
Solaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
0.98 [0.89 ; 1.08 ] Cao, 2020, Hung et al., 2020 (REV), Nojomi, 2020 (REV), Nojomi, 2020, RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, Solaymani-Dodaran, 2021 (REV), SOLIDARITY (lopi/rito), 2020 8 0% 9,355 moderate not evaluable deaths (time to event analysis only)detailed results REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
0.83 [0.65 ; 1.06 ] REMAP-CAP (lopinavir/ritonavir only), 2020 1 0% 645 NA not evaluable clinical deteriorationdetailed results ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
3.69 [0.37 ; 36.57 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
Huang, 2020 (REV) 0.73 [0.39; 1.37]
Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
0.67 [0.28 ; 1.60 ] Cao, 2020, Huang, 2020 (REV), Hung et al., 2020 (REV) 3 85% 149 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
Huang, 2020 (REV) 0.73 [0.39; 1.37]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
1.04 [0.61 ; 1.77 ] Cao, 2020, Huang, 2020 (REV), REMAP-CAP (lopinavir/ritonavir only), 2020 3 72% 866 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
1.59 [0.84 ; 3.03 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
3.16 [0.62 ; 16.06 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
Solaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33]
0.85 [0.49 ; 1.48 ] Cao, 2020, Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 3 84% 507 moderate not evaluable hospital dischargedetailed results Huang, 2020 (REV) 0.50 [0.29; 0.87]
RECOVERY, 2020 0.98 [0.91; 1.05]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
0.84 [0.67 ; 1.06 ] Huang, 2020 (REV), RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 3 75% 5,707 moderate not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18]
0.62 [0.32 ; 1.18 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
Huang, 2020 (REV) 0.75 [0.53; 1.06]
0.75 [0.53 ; 1.06 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV) 2 0% 47 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
Huang, 2020 (REV) 0.42 [0.04; 3.91]
0.25 [0.04 ; 1.53 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV) 2 0% 47 moderate not evaluable viral clearance detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
Huang, 2020 (REV) 0.83 [0.54; 1.29]
Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.56 [0.20 ; 1.55 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV), Hung et al., 2020 (REV) 3 73% 177 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.23 [0.10 ; 0.54 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48]
Huang, 2020 (REV) 0.92 [0.80; 1.06]
0.91 [0.79 ; 1.05 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020 (REV), Huang, 2020 (REV) 3 0% 119 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
Huang, 2020 (REV) 0.83 [0.42; 1.67]
0.79 [0.46 ; 1.35 ] ELACOI (Lopinavir/ritonavir), 2020 (REV), ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV) 3 0% 119 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44]
0.81 [0.46 ; 1.44 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64]
3.28 [0.79 ; 13.64 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
Hung et al., 2020 (REV) 4.28 [0.14; 130.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
0.99 [0.37 ; 2.68 ] Cao, 2020, Hung et al., 2020 (REV), REMAP-CAP (lopinavir/ritonavir only), 2020 3 61% 938 moderate not evaluable adverse eventsdetailed results Huang, 2020 (REV) 0.56 [0.04; 7.21]
0.56 [0.04 ; 7.21 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-20 16:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 509
- roots T: 290
